Evotec Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Evotec heeft een totaal eigen vermogen van €968.5M en een totale schuld van €470.1M, wat de schuld-eigenvermogensverhouding op 48.5% brengt. De totale activa en totale passiva bedragen respectievelijk €2.0B en €1.0B.

Belangrijke informatie

48.5%

Verhouding schuld/eigen vermogen

€470.05m

Schuld

Rente dekkingsratio	n/a
Contant	€303.27m
Aandelen	€968.47m
Totaal verplichtingen	€1.02b
Totaal activa	€1.99b

Recente financiële gezondheidsupdates

Recent updates

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 10

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Nov 05

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Aug 03

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Apr 10

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Mar 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Jan 09

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Oct 05

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Jun 28

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

May 14

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Feb 25

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Jul 29

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €698.1M ) EVT } overtreffen de korte termijn passiva ( €333.6M ).

Langlopende schulden: De kortetermijnactiva EVT ( €698.1M ) overtreffen de langetermijnschulden ( €688.7M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 17.2% ) EVT wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van EVT is de afgelopen 5 jaar gedaald van 68.8% naar 48.5%.

Schuldendekking: De operationele kasstroom van EVT is negatief, waardoor de schuld niet goed gedekt is.

Rentedekking: Er zijn onvoldoende gegevens om te bepalen of de rentebetalingen van EVT op haar schulden goed worden gedekt door EBIT.

Evotec Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Evotec SE announced delayed 20-F filing

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Consensus EPS estimates fall by 54%

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued